Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02516527 | A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors | completed | Phase 1 | 25 | Bristol-Myers SquibbINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT01916135 | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT03002376 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 47 | Regeneron PharmaceuticalsINDUSTRY | 4 | Apr 20, 2020 | clinicaltrials |
| NCT01103635 | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | completed | Phase 1 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02180061 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT00118313 | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 | — | Craig L Slingluff, JrOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02354690 | Vemurafenib and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 13 | Inge Marie SvaneOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT04274816 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | completed | Phase 1 | 13 | A.J.M. van den EertweghOTHER | 0 | Feb 18, 2020 | clinicaltrials |
| NCT02608034 | A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State | completed | Phase 1 | 32 | Genentech, Inc.INDUSTRY | 4 | Feb 12, 2020 | clinicaltrials |
| NCT03052205 | A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors(ILLUMINATE-101) | completed | Phase 1 | 54 | Idera Pharmaceuticals, Inc.INDUSTRY | 2 | Feb 11, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02379195 | Peginterferon and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 12 | Inge Marie SvaneOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03159117 | Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01684241 | RBL001/RBL002 Phase I Clinical Trial(MERIT) | completed | Phase 1 | 29 | BioNTech RNA Pharmaceuticals GmbHINDUSTRY | 2 | Jan 18, 2020 | clinicaltrials |
| NCT02035956 | IVAC MUTANOME Phase I Clinical Trial | completed | Phase 1 | 15 | BioNTech RNA Pharmaceuticals GmbHINDUSTRY | 2 | Jan 18, 2020 | clinicaltrials |
| NCT02424916 | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study(MelSort) | completed | Phase 1 / Phase 2 | 7 | Nantes University HospitalOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT02676869 | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma(TACTI-mel) | completed | Phase 1 | 24 | Immutep Australia Pty. Ltd.INDUSTRY | 1 | Dec 18, 2019 | clinicaltrials |
| NCT00145041 | Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction | completed | Phase 1 | 7 | Acrotech Biopharma Inc.INDUSTRY | 1 | Dec 12, 2019 | clinicaltrials |
| NCT00304460 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | completed | Phase 1 | 138 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT04180774 | Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer | completed | Phase 1 / Phase 2 | 80 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT00003897 | Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma | completed | Phase 1 | 18 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01196416 | Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01021059 | A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01213472 | Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma | completed | Phase 1 | 33 | GlaxoSmithKlineINDUSTRY | 8 | Oct 9, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT03007823 | High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT02045368 | Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R | completed | Phase 1 | 92 | IGF Oncology, LLCINDUSTRY | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01271803 | A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma | completed | Phase 1 | 131 | Hoffmann-La RocheINDUSTRY | 2 | Jul 29, 2019 | clinicaltrials |
| NCT01639911 | Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | completed | Phase 1 | 28 | University of Illinois at ChicagoOTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT01996202 | A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00438009 | A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03) | completed | Phase 1 | 9 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00636558 | Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)(PSX-X04) | completed | Phase 1 | 8 | ViralyticsINDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT00235482 | Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)(PXS-X02) | completed | Phase 1 | 3 | ViralyticsINDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01137006 | An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT00301067 | Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT01910181 | A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma | completed | Phase 1 | 46 | Hoffmann-La RocheINDUSTRY | 1 | May 29, 2019 | clinicaltrials |
| NCT01017185 | Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions | completed | Phase 1 | 28 | Takara Bio Inc.INDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT01603212 | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | completed | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02027961 | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | completed | Phase 1 | 68 | MedImmune LLCINDUSTRY | 4 | May 17, 2019 | clinicaltrials |
| NCT03472027 | Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma | completed | Phase 1 | 15 | BiocadINDUSTRY | 1 | May 9, 2019 | clinicaltrials |
| NCT02117362 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Providence Health & ServicesOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT00223899 | A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma | completed | Phase 1 | 26 | VicalINDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT00470015 | Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00844064 | Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 | completed | Phase 1 | 62 | Isarna Therapeutics GmbHINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2020source: clinicaltrials